Background: Global challenges related to access and benefit sharing (ABS) of biological resources have become a key concern in the area of research on herbal medicines, ethnopharmacology, drug discovery, and the development of other high value products for which Intellectual Property protection can be secured. While the Convention on Biological Diversity (CBD, Rio 1992) has been recognized as a huge step forward, the implementation of the Nagoya Protocol (NP) and of new forms of collaboration often remain unresolved, especially in the context of "the fair and equitable sharing of benefits arising from the utilization of genetic resources" (Convention on Biological Diversity, 2011). The vision and the specific implementation of this international treaty vary from country to country, which poses additional challenges.
View Article and Find Full Text PDFEthnopharmacological Relevance: The Peruvian Amazon holds more than 1000 plant species with commercial potential and the national sales of natural products derived from medicinal and aromatic plants have exceeded $ 400 million per year. Research and development activities carried out on the genetic and biochemical composition of Peruvian flora have to abide by national and international regulations, such as the Nagoya Protocol (NP).
Aim Of The Study: The aim of this paper is to describe the implications of the current implementation of the NP in Peru for performing research on national genetic resources.
Background: When in 1992 the Convention on Biological Diversity was adopted, it was a response to centuries of exploitative use of biodiversity and to a lack of recognition of the rights of the countries and regions of origin. At the same time, it was an outcome of the increasing drive, especially in many European and American countries, to ascertain more equitable sharing of wealth between the global North and South. It is a result of negotiations between states and driven by political consensus.
View Article and Find Full Text PDF